Medical Condition News

RSS

Morbid obesity among people with diabetes is increasing at a very alarming rate, says kidney expert

A Loyola University Health System study has found that one out of five Type 2 diabetics is morbidly obese -- approximately 100 pounds or more overweight.

23 Nov 2009

Inadequate asthma control is present in 26% to 45% of children, says review

Asthma is the commonest chronic disease in children and a major reason for admissions to hospital, yet inadequate asthma control is present in 26% to 45% of children, states a review http://www.cmaj.ca/embargo/cmaj071638.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

23 Nov 2009

Mutated IDH1 gene linked to the progression of gliomas

23 Nov 2009

"Wellness Workbook" from CIGNA to cope with holiday stress

Just in time to kick off the holiday season, now offers a free Wellness Workbook, “Coping With Holiday Stress: 10 Keys to Creating Healthy Holidays.” The workbook is available to the public at www.cigna.com.

23 Nov 2009

Middle age women who store fat on their waist more likely to develop dementia when they get older: Study

Women who store fat on their waist in middle age are more than twice as likely to develop dementia when they get older, reveals a new study from the Sahlgrenska Academy.

23 Nov 2009

MHCC's initiative for homeless people living with mental illness

Moncton is one of five cities selected by the Mental Health Commission of Canada (MHCC) for implementation of its ground-breaking national research project to find the best way to provide housing and services to people who are living with mental illness and homelessness. Using a 'Housing First' approach, the research project focuses on first providing people who are homeless with a place to live, and then the other assistance and services they require. The goal is to see if this approach is better than traditional 'care as usual'.

23 Nov 2009

BioTrends Research Group releases Wave 2 report on AMAG's Feraheme

BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15.

23 Nov 2009

Proteon Therapeutics commences PRT-201 Phase 1/2 clinical study in hemodialysis patients

Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.

23 Nov 2009

JDRF partners with the Canadian Government in diabetes research

Juvenile Diabetes Research Foundation (JDRF) Canada is pleased to announce its first partnership with the Government of Canada through the Federal Economic Development Agency of Southern Ontario. Through this innovative two-year partnership, the Government of Canada is committing $20 million and JDRF is making a matching contribution of $10 million to accelerate world-class diabetes research in Southern Ontario by implementing a clinical trial network for diabetes research.

23 Nov 2009

UT Southwestern Medical Center among 10 institutions to share $56 million from NIH as part of ICAC

UT Southwestern Medical Center is among 10 institutions selected by the National Institutes of Health to share $56 million over five years as part of the Inner City Asthma Consortium (ICAC).

23 Nov 2009

GI Dynamics to present interim data on its EndoBarrier Gastrointestinal Liner study

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that interim data from its ongoing clinical study of the EndoBarrier™ Gastrointestinal Liner in obese patients with type 2 diabetes will be presented by Eduardo G. Moura, M.D., Ph.D., director of endoscopy, digestive surgery department, Hospital das Clinicas, University of Sao Paulo, on Monday, November 23, 2009 at GASTRO 2009.

23 Nov 2009

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.

23 Nov 2009

FDA grants Fast Track designation for ARCA biopharma's Gencaro

ARCA biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of GencaroTM, the Company’s investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population.

23 Nov 2009

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."

23 Nov 2009

Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company’s novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009.

23 Nov 2009

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).

23 Nov 2009

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

ARIAD Pharmaceuticals, Inc. today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009.

23 Nov 2009

Most Canadians hope OAB symptoms will go away

A recent poll conducted by Leger Marketing, on behalf of the Powder Room - a national education program for those with overactive bladder (OAB) - asked 1,500 Canadians about their bladder health. The findings revealed that although people are experiencing OAB symptoms, most are choosing not to seek medical attention - perhaps assuming the frustrating and embarrassing symptoms will go away, or that they will just have to live with them.

23 Nov 2009

100th patient enrolled in Atrium Medical's iCAST Atrium Registry Ultrasound Study

Atrium Medical Corporation announced that the 100th patient was enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). The iCARUS study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease in the iliac artery.

23 Nov 2009

Kingston University receives £99,000 for cancer research

Scientists have begun a three-year study to analyse why cancer patients become resistant to treatments designed to fight the disease. A research team from Kingston University has been awarded £99,000 to investigate why some tumours are sensitive and respond to treatments and why other tumours do not.

23 Nov 2009

Medical Condition News

Morbid obesity among people with diabetes is increasing at a very alarming rate, says kidney expert

Inadequate asthma control is present in 26% to 45% of children, says review

Mutated IDH1 gene linked to the progression of gliomas

"Wellness Workbook" from CIGNA to cope with holiday stress

Middle age women who store fat on their waist more likely to develop dementia when they get older: Study

MHCC's initiative for homeless people living with mental illness

BioTrends Research Group releases Wave 2 report on AMAG's Feraheme

Proteon Therapeutics commences PRT-201 Phase 1/2 clinical study in hemodialysis patients

JDRF partners with the Canadian Government in diabetes research

UT Southwestern Medical Center among 10 institutions to share $56 million from NIH as part of ICAC

GI Dynamics to present interim data on its EndoBarrier Gastrointestinal Liner study

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

FDA grants Fast Track designation for ARCA biopharma's Gencaro

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

Most Canadians hope OAB symptoms will go away

100th patient enrolled in Atrium Medical's iCAST Atrium Registry Ultrasound Study

Kingston University receives £99,000 for cancer research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News